HAMBURG, Germany, June 27, 2025 /PRNewswire/ -- Yutong Bus ("Yutong", SHA: 600066), a global commercial vehicle manufacturer, showcased its green public transport innovations under the theme "Think Eco, Move Green" at the UITP Summit 2025, held from June 15-18 in Hamburg Germany. The flagship models included the battery electric intercity bus IC12E and the premium city bus U12.
Yutong IC12E：High Standard Battery Electric Intercity Bus – specifically designed for the European market
Yutong IC12E is specially designed and built for intercity operations in the European market. It comes with the advantages of long driving range, strong power, large capacity and superior quality.
On June 19, the IC12E embarked on a full-scenario challenge across four European countries: beginning in Hamburg, Germany, traversing through Copenhagen, Denmark, Gothenburg, Sweden, and ultimately reaching Oslo, Norway. This journey covers a variety of road conditions, including urban streets, highways, bridges, coastlines, and ramps, thereby fully showcasing the IC12E's exceptional performance and adaptability in diverse environments. The test data shows that over a distance of 1,272 km, with an average energy consumption of as low as 0.7 kWh/km (the vehicle was not fully loaded), demonstrating its extraordinary leading strength in new-energy technology.
 
the IC12E embarked on a full-scenario challenge across four European countries
During the test, the IC12E successfully completed a 510 km range-challenge between Germany and Denmark, with SOC dropped from 99% to 31%, and remaining range indicated 170 km. In the charging-efficiency test, the SOC rose from 13% to 99% in just 1 hour and 40 minutes when charging with a single gun. In the continuous uphill sections in Norway, the IC12E demonstrated a strong power-performance with a grade ability of 20%.
Yutong U12, a premium battery electric bus engineered for main urban routes
The U12, winner of the Busworld Design Label, features a 12-meter body capable of carrying up to 95 passengers, while incorporating a high-strength, robust closed-ring body structure and YESS battery safety system, combining safety, efficiency, comfort, and intelligent management.
Moving forward, Yutong will continue to create greater value for customers and enhance public travel experiences with green, safe and comfortable mobility solutions.
For more information, please visit https://en.yutong.com/.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Yutong Debuts New Generation Battery Electric Intercity Bus IC12E at UITP Summit Hamburg 2025, Showcasing Electrification Innovation
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
